| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | cyanoquinoline 11 | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | SB590885 | GDSC1000 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | JNK Inhibitor VIII | GDSC1000 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | ML312 | CTRPv2 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | -0.0028 | 0.9 |